STOCK TITAN
  1. Home
  2. News
  3. NVNO

enVVeno Medical Corporation - NVNO STOCK NEWS

Welcome to our dedicated news page for enVVeno Medical Corporation (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on enVVeno Medical Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect enVVeno Medical Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of enVVeno Medical Corporation's position in the market.

News
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Rhea-AI Summary
enVVeno Medical (NASDAQ:NVNO) announced positive topline efficacy data from the VenoValve pivotal trial at the 2024 Charing Cross International Symposium. The data showed an 8.46 average rVCSS improvement per patient, with 94% of patients showing clinical improvement at the 11-month follow-up. The Company aims to file for FDA approval in Q4 2024 to address the unmet medical need for severe deep venous CVI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.09%
Tags
none
-
News
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Rhea-AI Summary
enVVeno Medical (NVNO) announces the presentation of additional topline efficacy data from the VenoValve U.S. pivotal trial at the 46th Annual Charing Cross Symposium. The data will review the clinical status of subjects with Chronic Venous Insufficiency post VenoValve implantation, showing significant improvements in the revised Venous Clinical Severity Score (rVCSS). The presentation aims to demonstrate the VenoValve's Clinical Meaningful Benefit for patients with severe CVI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
News
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Rhea-AI Summary
enVVeno Medical (NVNO) appoints Andrew Cormack as Chief Commercial Officer, marking a significant step in the company's transition to commercialization of the VenoValve. The VenoValve, a surgical replacement venous valve for severe Chronic Venous Insufficiency patients, has shown promising efficacy data in a recent study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
management
News
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Rhea-AI Summary
enVVeno Medical (NVNO) to present at Virtual Investor Lunch Break event with CEO Robert Berman discussing business outlook and enVVeno Opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
conferences
-
News
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Rhea-AI Summary
enVVeno Medical Corporation (NVNO) reports positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve, showing significant clinical improvement. 97% of patients showed improvement in the revised Venous Clinical Severity Score (rVCSS), with 74% demonstrating clinically meaningful benefit. The average improvement per patient was 8 points, exceeding FDA requirements. The Company plans to seek FDA approval in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
none
-
News
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
enVVeno Medical Corporation (NVNO) reports $46.4 million in cash, achieving milestones in venous disease treatment. Topline efficacy data for VenoValve U.S. pivotal trial to be disclosed at VENOUS2024 American Venous Forum Annual Meeting. Strong financial position with funds to last through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
earnings
News
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Rhea-AI Summary
enVVeno Medical Corporation (NVNO) announces topline efficacy data from the VenoValve U.S. pivotal trial to be presented at the 2024 AVF Annual Meeting. The data will showcase clinical status improvements in severe Chronic Venous Insufficiency patients, addressing an unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.96%
Tags
none
-
News
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
Rhea-AI Summary
Veno Medical Corporation (NVNO) announced the availability of materials from the 50th Annual VEITH Symposium, including interviews with patients from the VenoValve pivotal trial. The Company is setting new standards of care for the treatment of severe Chronic Venous Insufficiency (CVI) and is also developing enVVe, a non-surgical replacement venous valve. The VenoValve aims to address the unmet medical need for effective treatments for severe CVI, with an estimated 2.5 new patients each year in the U.S. The Company expects to be ready for the enVVe pivotal trial in Q4 of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
-
News
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
Rhea-AI Summary
NVNO: enVVeno Medical Announces Positive Preliminary Safety Data from SAVVE U.S. Pivotal Trial for VenoValve at VEITH Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
News
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
enVVeno Medical Corporation reports financial results for Q3 2023, with $51.4 million cash on hand to fund operations through 2025. Achieved full enrollment for VenoValve U.S. pivotal trial and expedited development plan for enVVe transcatheter-based replacement venous valve.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
earnings
Stock NVNO logo
enVVeno Medical Corporation

Nasdaq:NVNO

NVNO Rankings

#4520 Ranked by Market Cap
#3256 Ranked by Stock Gains
N/A Ranked by Dividends

NVNO Stock Data

66.45M
12.56M
0.39%
35.04%
6.17%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Irvine

About NVNO

hancock jaffe laboratories, inc. is a medical device company based out of 2807 mcgaw ave, irvine, ca, united states.